

Maria Carmina Castiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8417370/publications.pdf>

Version: 2024-02-01

27
papers

1,954
citations

361296

20
h-index

526166

27
g-index

28
all docs

28
docs citations

28
times ranked

3070
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of anti-CD45 α saporin as conditioning agent for RAG deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 309-320.e6.	1.5	27
2	Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation. <i>Frontiers in Genome Editing</i> , 2021, 3, 618378.	2.7	27
3	Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 607926.	2.2	11
4	Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 825-838.	1.5	50
5	Platelets in Wiskott-Aldrich syndrome: Victims or executioners?. <i>Journal of Leukocyte Biology</i> , 2018, 103, 577-590.	1.5	14
6	Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1272-1284.	1.5	28
7	Neutrophils drive type I interferon production and autoantibodies in patients with Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1605-1617.e4.	1.5	21
8	Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 928-941.e8.	1.5	28
9	Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	176
10	In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells. <i>Frontiers in Immunology</i> , 2017, 8, 490.	2.2	10
11	Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic <i>RAG1</i> defects. <i>Journal of Experimental Medicine</i> , 2016, 213, 355-375.	4.2	61
12	IL-10 Critically Modulates B Cell Responsiveness in <i>Rankl</i> ^{-/-} Mice. <i>Journal of Immunology</i> , 2015, 194, 4144-4153.	0.4	8
13	B-cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 692-702.e2.	1.5	41
14	Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. <i>Journal of Clinical Investigation</i> , 2015, 125, 3941-3951.	3.9	43
15	Wiskott-Aldrich syndrome protein deficiency in natural killer and dendritic cells affects antitumor immunity. <i>European Journal of Immunology</i> , 2014, 44, 1039-1045.	1.6	29
16	B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 799-806.e10.	1.5	30
17	Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B-cell compartment in humans. <i>Journal of Autoimmunity</i> , 2014, 50, 42-50.	3.0	72
18	Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. <i>Science</i> , 2013, 341, 1233151.	6.0	900

#	ARTICLE	IF	CITATIONS
19	Preclinical Safety and Efficacy of Human CD34+ Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. <i>Molecular Therapy</i> , 2013, 21, 175-184.	3.7	72
20	Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. <i>Journal of Experimental Medicine</i> , 2013, 210, 355-374.	4.2	49
21	Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. <i>Journal of Cell Biology</i> , 2013, 200, i6-i6.	2.3	0
22	Autoimmunity in Wiskott-Aldrich Syndrome: An Unsolved Enigma. <i>Frontiers in Immunology</i> , 2012, 3, 209.	2.2	110
23	Dendritic cell functional improvement in a preclinical model of lentiviral-mediated gene therapy for Wiskott-Aldrich syndrome. <i>Gene Therapy</i> , 2012, 19, 1150-1158.	2.3	8
24	SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. <i>Cardiovascular Research</i> , 2012, 96, 381-390.	1.8	40
25	Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1376-1384.e5.	1.5	34
26	Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: Analysis of function and distribution in lymphoid organs. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 439-448.e8.	1.5	31
27	Insulin-like growth factor-1 protects from vascular stenosis and accelerates re-endothelialization in a rat model of carotid artery injury. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1920-1928.	1.9	33